Business
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2022
JI'AN, China, Aug. 16, 2022 /PRNewswire/ -- Universe Pharmaceuticals INC (the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor in China,
About this update from Universe Pharmaceuticals Inc
[{"type":"text","content":"JI'AN, China, Aug. 16, 2022 /PRNewswire/ -- Universe Pharmaceuticals INC (the \"Company\") (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of fiscal year 2022 ended March 31, 2022.\nMr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, \"During the first six months of fiscal year 2022, we have navigated business uncertainties and adjusted our business strategy to offset the impact of reduced product sales volume due to the resurgence of COVID-19 cases and related lockdowns. As a result, we generated $24.2 million in revenue for the six months ended March 31, 2022, slightly lower than the same period of last year, demonstrating the considerable efforts we made during this challenging period. To complement our offline sales channels, we established a strategic priority in developing online business channels, which helps us to seize the opportunity and is expected to drive our business growth in the fast-evolving market. Through executing our growth strategy of emphasizing digital marketing and expanding our sales on e-commerce platforms, we expect to improve our brand recognition, deliver products to more customers, and expand our business scale. Looking forward, we intend to continue implementing our expansion strategy, which we believe will allow us to achieve greater market penetration and expand our customer base, with the goal creating long-term value for our shareholders.\"\nFinancial Highlights for the Six Months Ended March 31, 2022\nFor the Six Months Ended March 31,\n($ millions, except per share data)\n2022\n2021\n% Change\nRevenues\n24.2\n24.3\n-0.4 %\nIncome from operations\n2.7\n9.6\n-71.8 %\nNet income \n1.7\n7.1\n-75.8 %\nEarnings per share\n0.08\n0.44\n-81.8 %\n \nRevenues slightly decreased by 0.4% to $24.2 million for the six months ended March 31, 2022 from $24.3 million for the six months ended March 31, 2021, primarily attributable to decreased sales volume of the Company's traditional Chinese medicine derivatives (\"TCMD\") products and third-party products by 2,454,463 units, or 17.3%, and the decreased average selling price of third-party products by $0.32 per unit, or 14.7%, partially offset by the increased average selling price of the Company's TCMD products by $0.74 per unit, or 50.7%.Income...